Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 215
Healthy volunteers: no

Brief summary:
For subjects in Europe that have already participated in either Study SPD503-315 or SPD503-316. This is an extension study that will allow participants access to Extended-release Guanfacine Hydrochloride (HCl) for up to 2 years. This study will help the sponsor evaluate long-term safety and tolerability of Extended-release Guanfacine HCl (SPD503).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Extended-release Guanfacine HCl (Intuniv, SPD503)
Intervention descriptions: intervention 1: Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age

Protocol document: